An interview with Robert Klein is presented about the initiative which created the California Institute for Regenerative Medicine (CIRM). Klein discussed a three-stage process in the selection of grants for embryonic stem cell research. He has explained why certain kinds of information about the review process is not available to the public. He has acknowledged that the criticism of the patenting policy of CIRM is understandable.